Health

Pharmacy mixes up breast cancer drug, children’s fluoride

As many as 50 families may have been affected by a New Jersey CVS Pharmacy’s mixup of children’s fluoride prescriptions, and the breast cancer drug tamoxifen, the Chatham Courier reports.

According to the newspaper, parents who had their children’s fluoride prescriptions filled at the Chatham, N.J., location are between Dec. 20 and Feb. 20 are being asked to check that the pill bottles don’t contain tamoxifen.

The paper quotes a CVS spokesman as saying the company is “deeply sorry for the mistake.”

See ...

continue reading...

Another delay in Yasmin case

For the second time in three months, the U.S. District Court has delayed trial deadlines in the cases over Yaz/Yasmin/Beyaz birth control for 60 days.

Chief Judge David R. Herndon of the Southern District of Illinois announced the delay on Feb. 29. The delay will allow the parties in the case more time to negotiate.

Lopez McHugh is representing multiple plaintiffs against Bayer Healthcare, manufacturer of the birth control pills Yasmin, Yaz, Beyaz, and Ocella. Lopez McHugh’s claim, supported by a ...

continue reading...

Gene therapy promising for Alzheimer’s treatment

A recent study linking Alzheimer’s disease with the repression of gene activity in the brain is a promising development in potential treatment of the disease, according to a recent news release by the National Institutes of Health.

“These findings provide a glimpse of the brain shutting down the ability to form new memories gene by gene in Alzheimer’s disease, and offer hope that we may be able to counteract this process,” said Roderick Corriveau, Ph.D., a program director at NIH’s National ...

continue reading...

Coalition demands more rigorous FDA screening

A coalition of patient, consumer, and public health groups urged the federal Food and Drug Administration to require more rigorous testing before a medical device used for addressing complications from aneurysm treatments can be sold.

“This decision by FDA sets a bad precedent for approving new devices,” said Lisa McGiffert, Director of Consumers Union’s Safe Patient Project. “Medical devices intended to save lives should require the FDA’s most rigorous safety testing. Bypassing such testing up front can put hundreds of thousands ...

continue reading...

Members of Congress: Close FDA loophole

Four Democratic U.S. Representatives have introduced legislation designed to close a major loophole in the process by which the federal Food and Drug Administration approves medical devices. The legislation’s sponsors specifically cite vaginal mesh implants and metal-on-metal hip implants as dangerous and defective devices that have made it onto the market as a result of that loophole.

A news release from ...

continue reading...

FDA Panel: Yaz/Yasmin Birth Control Labeling Should Reflect Risks

A Food and Drug Administration panel of experts ruled that the labeling of the popular birth-control pills Yaz and Beyaz should be updated to reflect recent data showing the drug poses a higher risk of causing blood clots than older contraceptives.

Already, 10,458 lawsuits have been filed in federal court against pharmaceutical giant Bayer AG, maker of the contraceptives Yaz, Beyaz, and Yasmin. Plaintiffs claim they weren’t warned of the drug’s harmful side effects, according to the Southern District of ...

continue reading...
Page 110 of 120 «...8090100108109110111112...»